Fibrinogen: A cardiovascular risk factor;El fibrinógeno: Factor de riesgo cardiovascular

Investigacion Clinica

Volumn 43, Issue 4, 2002, Pages 291-301

  Espinosa, Raúl A ^a  

^a Hospital Miguel Perez Carreno   (Venezuela)

Author keywords

Atherothrombosis; Cardiovascular disease; Fibrinogen

Indexed keywords

FIBRINOGEN;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL STUDY; FIBRINOGEN BLOOD LEVEL; HEART FUNCTION; HOMEOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; POPULATION; RECURRENT DISEASE; THROMBOSIS; VENEZUELA;

EID: 17544387985     PISSN: 05355133     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Losner S, Volk BW, Wilensky ND. Fibrinogen concentration in acute myocardial infarction. Arch Inter Med 1954;93:231-238.
2. Cook NS, Ubben D. Fibrinogen as a major risk factor in cardiovascular disease. Trends Pharmacol Sci 1990;11:444-451.
3. Rosenson RS. Myocardial injury, the acute phase response and lipoprotein metabolism. J Am Coll Cardiol 1993;22:93-98.
4. Baumann H, Richards C, Gauldie J. Interaction among hepatocyte-stimulating factors, interleukin-1 and glucocorticoids for regulation of acute phase plasma protein in human hepatoma cells. J Immunol 1987;139:4122-4128.
5. Wong ND, Ridker PM. Thrombosis, inflammation and infection. En: Wong ND, Black HR, Gardin JM, Eds: Preventive Cardiology. McGraw-Hill, Health Professions Division 2000:269-286.
6. Cairns JA, Lewis HD, Meade TW, Sutton GC, Theroux P. Antithrombotic agents in coronary artery disease: Fourth ACCP Consensus Conference on Antithrombotic Therapy. Chest 1995;108(suppl):380S-400S.
7. Sanz G, Castañer A, Betrui A, Magriña J, Roig E, Coll S, Paré JC, Navarro-López F. Determinants of prognosis in survivors of myocardial infarction: A prospective clinical angiographic study. N Engl J Med 1982;306:1065-1070.
8. Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR, Santamore WP. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease?. Circulation 1988;78:1151-1166.
9. Heinrich J, Assmann G. Fibrinogen and cardiovascular risk. J Cardiovasc Risk 1995;2:197-205.
10. Naito M, Hayashi T, Kuzuya M, Funaki C, Asai K, Kusuya F. Effects of fibrinogen and fibrin on the migration of vascular smooth muscle cells in vitro. Atherosclerosis 1990; 83:9-14.
11. Smith EB. Transport, interactions and retention of plasma proteins in the intima. Eur Heart J 1990;11(suppl E):72-81.
12. Andreotti F, Burzotta F, Maseri A. Fibrinogen as a marker of inflammation: A clinical view. Blood Coagul Fibrinolysis 1999;(suppl 1):S3-S4.
13. Sadoshima S, Tavaka K. Fibrinogen and low-density lipoprotein in the development of cerebral atherosclerosis. Atherosclerosis 1979;34:93-103.
14. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischemic heart disease: Principal results of the Northwick Park Heart study. Lancet 1986;2(8506): 533-537.
15. Wilheimsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311:501-505.
16. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease: The Framingham study. JAMA 1987;258:1183-1186.
17. Sweetman PM, Thomas HF, Yarnell JWG, Beswick AD, Baker IA, Elwood PC. Fibrinogen viscocity and the ten year incidence of ischaemic heart disease: The Caerphilly and Speedwell Studies. Eur Heart J 1996;17:1814-1820.
18. Heinrich J, Balleisen L, Schulte H, Assmann G, Van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: Results from the PROCAM study in healthy men. Arterioseler Thromb 1994; 14:54-59.
19. Wu KK, Folsom AR, Heiss G, Davis CE, Conlan MG, Barnes R. for the ARIC study Investigators. Association of coagulation factors and inhibitors with carotid artery atherosclerosis risk in communities (ARIC) study. Ann Epidemiol 1992;2: 471-480.
20. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997;96:1102-1108.
21. Scarabin PY, Aillaud MF, Amouyel P, Evans A, Luc G, Ferrières J, Arveiler D, Juhan-Vague I. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction. The Prime Study. Thromb Haemost 1998; 80:749-756.
22. Thompson SG, Kienast J, Pyke DM, Havarkate F, Van de Loo JCW for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-641.
23. Woodward M, Lowe GDO, Rumley A, Tunstall-Pedoc H. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and woman: Scottish Heart Health Study. Eur Heart J 1998; 19:55-62.
24. Ma J, Hennekens CH, Ridker PM, Stampfer MJ. A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study. J Am Coll Cardiol 1999;33:1347-1352.
25. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med 1993;118:956-963.
26. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, c-reactive protein, albumin or leukocyte count with coronary heart disease. Meta-analyses of prospective studies. JAMA 1998;279: 1477-1482.
27. Maresca G, Di Blasio A, Marchioli R, Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction. An update. Arterioscler Thromb Vasc Biol 1999;19:1368-1377.
28. Arocha-Piñango CL. El fibrinógeno: Su relación con la enfermedad arterial coronaria. Resultados preliminares de un estudio multicéntrico. Rev Chilena Cardiol 1996;15:66-77.
29. Mijares ME, Rodriguez-Larralde A, Espinosa R, Nagy E, Castillo L, Carvajal Z, Ojeda A, Gil A, Lundberg U, Arocha-Piñango CL. Fibrinógeno y otros parámetros hemostáticos en la enfermedad coronaria isquémica. Infor Med 2000;2: 613-628.
30. Stone MC, Thorp KM. Plasma fibrinogen: A major coronary risk factor. J R Coll Gen Pract 1985;35:565-569.
31. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: Results from the prospective Göttinger Risk Incidence and Prevalence Study (GRPIS). Eur J Clin Invest 1994;24:444-453.
32. AHA/ACC. Guidelines for preventing heart attack and death in patients wit atherosclerotic cardiovascular disease: 2001 update. Circulation 2001;104:1577-1579.
33. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal woman. JAMA 1998;280:605-613.
34. The writing group of the Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Effects of estrogen or estrogen/progestin on heart disease risk factors in postmenopausal woman. JAMA 1995;273:199-208.
35. Castillo L, Richiusa R. Fibrinógeno y ejercicio físico programado. Avances Cardiol 2001;21(supl 1):59.
36. Conard J, Lecrurbier C, Scarabin PY, Horellow MH, Samama M, Bousser MG. Effects of long term administration of ticlopidine on platelet function and hemostatic variables. Thromb Res 1980;20: 143-148.
37. Lip GYH, Lowe GD, Metcalf MJ, Rumley A, Dunn FG. Effects of warfarin therapy on plasma fibrinogen, von Willebrand factor and fibrin D-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysms. Am J Cardiol 1995;76:453-458.
38. Rosenson RS, Lowe GD. Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis 1998;140:271-280.
39. Branchi A, Rovellini A, Sommariva D, Gugliandolo AG, Fasoli A. Effects of three fibrate derivates and two HMG-CoA reductase inhibitors on plasma fibrinogen in patients with primary hypercholesterolemia. Thromb Haemost 1993;70:241-243.
40. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, De Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-853.
41. Barasch F, Benderly M, Graff F. for the principal investigators of the BIP Study Group: Plasma fibronogen levels and their correlates in 6457 coronary heart disease patients: the Bezafibrate Infarction Prevention (BIP) study. J Clin Epidemiol 1995; 48:767-765.
42. Farnier M, Davignon J. Current and future treatment of hyperlipidemia: The role of statins. Am J Cardiol 1998;82:3J-10J.
43. Rosenson RS, Tangney CC. Anti-atherothrombotic properties of statins. Implications for cardiovascular event reduction. JAMA 1998;279:1643-1650.
44. Graham J. Statins and coronary artery disease. It's the clinical endpoints that count. Brit J Clin Pract 1997;51:2-3.